Standard Biotools Inc. (LAB) Stock Price & Analysis
Standard Biotools Inc. (LAB) rose 10.33% to USD 0.89 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
LAB last closed at USD 0.8; the session ranged USD 0.79–0.91 on volume of 8,325,038 shares. Market capitalization is $346.91M, with a 52-week range of USD 0.79–1.72 (NMS). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 0.89 |
|---|---|
| Change | ▲ 10.33% (up) |
| Previous Close | USD 0.8 |
| Open | USD 0.81 |
| Day Range | USD 0.79 – 0.91 |
| 52-Week Range | USD 0.79 – 1.72 |
| Volume | 8,325,038 shares |
| Market Cap | $346.91M |
| Exchange | NMS |
Technical Analysis (LAB)
Nexqual's technical model rates LAB "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.86 (neutral) |
| vs SMA50 | Below (USD 0.98) |
| MACD | 0.01 (positive) |
Analyst Ratings (LAB)
Wall Street analysts rate LAB "Buy" based on 2 analysts, with a mean price target of USD 1.55 (range USD 1.35–1.75), per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 1.55 |
| High Target | USD 1.75 |
| Low Target | USD 1.35 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (LAB)
| Next Earnings Date | 2026-05-05 |
|---|---|
| Revenue Estimate | $20.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.02 vs est -0.02 ▲ beat |
| 2025-12-31 | USD 0.07 vs est -0.03 ▲ beat |
| 2025-09-30 | USD -0.04 vs est -0.02 ▼ miss |
| 2025-06-30 | USD -0.04 vs est -0.04 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (LAB)
| Total Revenue | $86.25M |
|---|---|
| Revenue Growth (YoY) | +4.60% |
| Gross Margin | +53.27% |
| Operating Margin | -44.53% |
| Profit Margin | +90.67% |
| ROE | -9.86% |
| Debt / Equity | 5.26 |
| Current Ratio | 12.36 |
| Total Cash | $455.18M |
| Total Debt | $29.49M |
| Free Cash Flow | $-13.44M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (LAB)
Nexqual rates Standard Biotools Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Critical — Revenue -51% YoY (annual), sharp decline |
|---|---|
| Profitability | Mixed — Gross margin 53%, operating -45% |
| Balance Sheet | Strong — $455M cash vs $29M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$13M, burning cash |
| Efficiency | Critical — ROE -10%, ROA -8.1% |
Ownership (LAB)
| Insider Ownership | +1.46% |
|---|---|
| Institutional Ownership | +76.75% |
| Shares Outstanding | 391.46M |
| Float | 210.47M |
| Short % of Float | +5.48% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (LAB)
Standard Biotools Inc. is led by Michael Egholm (age 62), President, CEO & Director, per Nexqual as of June 9, 2026 at 23:49 UTC.
| President, CEO & Director | Michael Egholm (age 62) |
|---|---|
| Chief Financial Officer | Hanjoon Kim (age 54) |
| Vice President of Investor Relations | John Graziano |
Major Backers & Investors (LAB)
Notable institutional backers of Standard Biotools Inc. include Casdin Capital, LLC, Viking Global, MAK Capital One LLC, according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Casdin Capital, LLC | 22.74% |
| Viking Global | 15.02% |
| MAK Capital One LLC | 6.7% |
| Long Focus Capital Management, LLC | 4.1% |
| Hollow Brook Wealth Management LLC | 1.45% |
| Neuberger Berman Group, LLC | 1.19% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.42% |
| Vanguard Group | 6.86% |
| Geode Capital | 1.87% |
| State Street | 1.68% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
From Standard Biotools Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
- The company operates through Proteomics and Genomics segments.
- Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses.
- The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | USD 7.9 | ▲ 2.6% |
| LYEL | Lyell Immunopharma, Inc. | USD 12.7 | ▲ 6.1% |
| CTKB | Cytek Biosciences, Inc. | USD 4.13 | ▲ 0.98% |
| FDMT | 4D Molecular Therapeutics, Inc. | USD 9.23 | ▲ 6.83% |
| ANNX | Annexon, Inc. | USD 5.2 | ▼ 1.7% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.